Generics, pharmaceuticals, India, compulsory licenses, Patent Act, TRIPS, biosimilars, Nexavar, Herclon, Roche Holdings, Bayer, innovation, access to medicine, Jordan.
India faces a drug access issue. By using compulsory licenses India can increase access to pharmaceuticals through generics and protect innovation of pharmaceutical patents. Similarly situated countries will benefit from India’s model to improve affordable generics while requiring strict voluntary license application requirements and drug trials for biosimilars.
BYU ScholarsArchive Citation
"India's Compulsory License Model: Increased Pharmaceutical Access and Innovation Coexist,"
Brigham Young University Prelaw Review: Vol. 33
, Article 5.
Available at: https://scholarsarchive.byu.edu/byuplr/vol33/iss1/5